Introduction
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics.
Scope of this report
- Thorough examination of the top eight cancer therapeutic antibodies on the market.
- The race towards the next generation of therapeutic antibodies and improved drug delivery methods there of.
- Antibody deals are on the rise, where of those targeting oncology is the single most active area.
- Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Research and analysis highlights
The commercial and therapeutic success of antibodies will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. The first-generation formulations of therapeutic antibodies will be facing heavy competition from biogeneric companies as their profitable antibody drugs comes off patent in the future. Among the different strategies (e.g., antibody engineering, changes in primary structure, fusions, chemical modifications glycosylation, pegylation, polymer conjugates), the approach of miniaturizing and delivering antibody drugs is the most promising because it permits better release of active drugs.
Key reasons to read this report
- One source to the top cancer therapeutic antibodies on the market.
- Key insights into the second wave in the lucrative field of therapeutic antibodies.
- Competitive landscape assessment, including deals, technologies and more than 100 companies in the field and close to 100 cancer therapeutic antibodies.
1. Executive Summary
2 Cancer Highlights
3 Methodology
4 4.1 List of Boxes
4.2 List of Tables
5 Key Developmental Strategies
6 Treating Colorectal Cancer
6.1 Avastin
6.1.1 Avastin -Major Developmental Milestones
6.1.2 Sales Predictions on Avastin
6.1.3 Avastin Related Studies
6.2 Erbitux
6.2.1 Erbitux -Major Developmental Milestones
6.2.2 Sales Predictions on Erbitux
6.2.3 Erbitux Related Studies
7 Treating Lymphomas
7.1 Rituxan
7.1.1 Sales Predictions on Rituxan
7.1.2 Rituxan -Major Developmental Milestones
7.1.3 Rituxan Related Studies
7.2 Bexxar
7.2.1 Sales Predictions on Bexxar
7.2.2 Bexxar -Major Developmental Milestones
7.2.3 Bexxar Related Studies
7.3 Zevalin
7.3.1 Sales Predictions on Zevalin
7.3.2 Zevalin -Major Developmental Milestones
7.3.3 Zevalin Related Studies
8 Treating Leukemias
8.1 ALL
8.2 CLL
8.3 AML
8.4 CML
8.5 Campath
8.5.1 Campath -Major Developmental Milestones
8.5.2 Campath Related Studies
8.6 Mylotarg
8.6.1 Mylotarg Related Studies
9 Treating Lung cancer
9.1 Cotara
10 Antibody Deals on the Rise
10.1 Antibody Deals in Phase III
10.1.1 Deal Situation: MDX 010
10.1.2 Deal Situation: WX G250
10.1.3 Deal Situation: Zanolimumab
10.2 Antibody Deals in Phase II
10.2.1 Deal Situation: Mapatumumab
10.2.2 Deal Situation: GCR 3888
10.2.3 Deal Situation: MDX 070
10.2.4 Deal Situation: CDP 860
10.2.5 Deal Situation: Tru-Scint OV
10.2.6 Deal Situation: SC 1
10.2.7 Deal Situation: PRO 70769
10.2.8 Deal Situation: XR 303
10.2.9 Deal Situation: HumaRAD-HN
11 New Approaches in Antibody Delivery and Design – The Next Generation
11.1 How to Make Them Smaller and Different?
11.2 Biomaterials in Sustained Delivery Applications
11.2.1 Implants
11.3 Gene delivery – the Future?
11.3.1 Delivery Vehicles for DNA
11.3.2 Gene Delivery in Commercialization
12 Current Analysis of Mabs in Clinical Development
12.1.1 Prostate Cancer Therapeutics
12.1.2 Breast Cancer Therapeutics
12.1.3 Colorectal Cancer Therapeutics
12.1.4 Melanoma Therapeutics
12.1.5 Hematological Cancers Therapeutics
12.2 Mabs in Late Stage of Development
12.2.1 MAbs in Phase III Clinical Development
12.2.2 Mabs in Phase II Clinical Development
13 Appendix I: Cancer Therapeutic Antibodies in Clinical Development
14 Appendix II: Discontinued Projects - A Five Year Recapitulation
15 Appendix III: Selected Company Profiles
16 Disclaimer
17 Drug Index
18 Company Index
4.1 List of Boxes
Box 1: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology
Box 2: Marrion’s Drug Delivery Technology
Box 3: Quick Facts - CeaVac.
Box 4: Quick Facts - Elsilimomab
Box 5: Quick Facts – IGN 101
Box 6: Quick Facts – IMC-BEC2
Box 7: Quick Facts – MDX 010
Box 8: Quick Facts – ONYVAX 105
Box 9: Quick Facts - Ovare
Box 10: Quick Facts – Panitumumab
Box 11: Quick Facts - RENCARNEX.
Box 12: Quick Facts - Nimotuzumab
Box 13: Quick Facts - RENCARNEX
Box 14: Quick Facts - Lintuzumab
Box 15: Quick Facts - Zanolimumab
Box 16: Quick Facts – ABT-510
Box 17: Quick Facts – BB 10901
Box 18: Quick Facts – CP-675206
Box 19: Quick Facts – CNTO-328
Box 20: Quick Facts - Ecromeximab
Box 21: Quick Facts – EMD-273063
Box 22: Quick Facts – WX-G250RIT
Box 23: Quick Facts – HGS-ETR1. 97
Box 24: Quick Facts – HuMax-CD20
Box 25: Quick Facts – HuMax-EGFr2
Box 26: Quick Facts – Galiximab
Box 27: Quick Facts – PROXINIUM
Box 28: Quick Facts – RAV12
Box 29: Quick Facts –SGN-15
Box 30: Quick Facts –SGN-30
Box 31: Quick Facts – VEGF-Trap
Box 32: Quick Facts – MEDI 522
Box 33: Quick Facts – Volociximab.
Box 34: Quick Facts – Zanolimumab
4.2 List of Tables
Table 1: Summary of Strategies Enhancing Antibody Function
Table 2: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies
Table 3: Drug Delivery Companies with Cancer Focus
Table 4: FDA Approved Polymer-based Drug Delivery Systems for Cancer
Table 5: Antibody Therapeutics in Prostate Cance
Table 6: Antibody Therapeutics in Breast Cancer
Table 7: Antibody Therapeutics in Colorectal Cancer
Table 8: Antibody Therapeutics in Melanoma
Table 9: Antibody Therapeutics in Hematological Cancer
Table 10: MDX-010’s Collaborative History and Landscape
Other selected research from the 'Cancer Highlights' category:
Cancer Vaccines Fantasy or Future?
Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
Other selected research from the 'Oncology' category:
Triple Analysis: Leukemia, Lymphoma and Peptides
Triple Analysis: Lung Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
Other selected research from the 'Immunomodulators' category:
Analytical Tool - Cancer Immunotherapy
Immunotherapy in Oncology Drug Pipeline Update 2012